InvestorsHub Logo
Followers 30
Posts 7916
Boards Moderated 5
Alias Born 04/05/2005

Re: bernoulli post# 36

Wednesday, 05/17/2006 12:12:31 PM

Wednesday, May 17, 2006 12:12:31 PM

Post# of 293
Nektar Therapeutics "buy"
Wednesday, May 17, 2006 4:56:33 AM ET
WR Hambrecht & Co

NEW YORK, May 17 (newratings.com) - Analysts at WR Hambrecht maintain their "buy" rating on Nektar Therapeutics (NKTR.NAS). The target price is set to $30.

In a research note published yesterday, the analysts mention that the company's Exubera product has been approved and is to be launched soon. Nektar Therapeutics has implemented cost cutting measures on everything except Exubera, which is expected to boost the company's earnings over the next several years, the analysts say. The recent decline in the company's share price offers an attractive investment opportunity, WR Hambrecht adds.

http://www.newratings.com/analyst_news/article_1277370.html



"Growth is all that matters!" CRAMER

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NKTR News